Takeda Says Bid To Buy IDM Pharma Of U.S. Now Completed

Takeda Pharmaceutical says its tender offer for $58 million worth of shares of U.S.-based IDM Pharma has been accepted, completing the acquisition. The U.S. cancer-drug specialist is to become a wholly owned subsidiary of Takeda. On the same day Takeda announced completion of the merger, it also said it has begun Phase III studies of its TAK-536 drug to treat high blood pressure, a follow-up drug to one of its best-sellers, Blopress. (Click here for more - a subscription may be required